

Interim results

October 2025



Where Complexity meets Clarity

Actionable AI Powered Risk Scores for Every Patient

Disclaimer

THE SLIDES THAT FOLLOW, ANY VIDEO RECORDING OR ORAL BRIEFING IN CONNECTION WITH THESE SLIDES, ANY QUESTION-AND-ANSWER SESSION(S) THAT FOLLOW(S) THE ORAL PRESENTATION, HARD OR SOFT COPIES OF THESE SLIDES AND ANY MATERIALS DISTRIBUTED AT, OR IN CONNECTION WITH THESE SLIDES (TOGETHER, THE "PRESENTATION") ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES (OR ANY OF ITS TERRITORIES OR POSSESSIONS), CANADA, AUSTRALIA, NEW ZEALAND, THE REPUBLIC OF IRELAND, THE REPUBLIC OF SOUTH AFRICA, JAPAN OR ANY JURISDICTION WHERE SUCH DISTRIBUTION IS UNLAWFUL. FURTHERMORE, THIS PRESENTATION MAY NOT BE PUBLISHED, DISTRIBUTED, COPIED, REPRODUCED, IN WHOLE OR IN PART, OR OTHERWISE DISSEMINATED, DIRECTLY OR INDIRECTLY, TO THE PRESS. FAILURE TO COMPLY WITH THIS RESTRICTION MAY, INTER ALIA, CONSTITUTE A VIOLATION OF APPLICABLE SECURITIES LAWS.

ANY PERSON WHO WISHES TO RECEIVE THIS PRESENTATION MUST FIRST SATISFY THEMSELVES THAT THEY ARE NOT SUBJECT TO ANY LOCAL REQUIREMENTS THAT PROHIBIT OR RESTRICT THEM FROM DOING SO. ANY FAILURE TO COMPLY WITH THIS REQUIREMENT MAY RESULT IN A VIOLATION OF APPLICABLE SECURITIES LAWS.

This Presentation is being supplied to you by Verici DX plc (the "Company") solely for your information. **The content of this Presentation has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 ("FSMA"). This Presentation does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities of the Company nor shall it or any part of it nor the fact of its distribution form the basis of, or be relied on in connection with, any contract, commitment or investment decision in relation to any such matter nor does it constitute a recommendation regarding the securities of the Company.** Investors and prospective investors in securities of the Company are required to make their own independent investigation and appraisal of the business and financial condition of the Company and the nature of the securities. This Presentation should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers, agents, employees or advisers. Each party to whom this Presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. In particular, any estimates or projections or opinions contained herein necessarily involve significant elements of subjective judgment, analysis and assumptions and each recipient should satisfy itself in relation to such matters.

The Presentation is directed only at: (a) persons who are or who are reasonably believed to be shareholders of the Company, (b) in the United States, to a person who is either (i) a "qualified institutional buyer" as defined in Rule 144A under the United States Securities Act of 1933, as amended ("**US Securities Act**"), or (ii) an "accredited investor" as defined in Rule 501(a) of Regulation D under the US Securities Act, (c) persons in member states of the European Economic Area ("**EEA**") who are "qualified investors" within the meaning of Article 2(e) of Regulation (EU) 2017/1129, as amended from time to time, (d) persons in the United Kingdom who are "qualified investors" within the meaning of Article 2(e) of the Prospectus Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 (as amended), and who are either: (i) persons who have professional experience in matters relating to investments and who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended)(the "**Order**"), (ii) high net worth companies, unincorporated associations and other bodies in the United Kingdom falling within the meaning set out in Article 49 of the Order, or (iii) those persons to whom it may otherwise be lawfully communicated or distributed to (collectively, all such persons being referred to as "**relevant persons**"). The Presentation is directed only at relevant persons. Other persons should not act or rely on this Presentation or any of its contents.



Disclaimer (continued)

The shares of the Company have not been, and will not be, registered under the US Securities Act, or under the applicable securities law or with any securities regulatory authority of any state or jurisdiction of the United States, and may not be offered or sold, resold, transferred or delivered, directly or indirectly, in the United States or to, or for the account or benefit of, US Persons (as defined in Regulation S under the US Securities Act), except pursuant to an exemption from, or a transaction not subject to, the registration requirements of the US Securities Act. Neither this Presentation nor any part or copy of it may be taken, transmitted or distributed, directly or indirectly, by any means (including electronic transmission) in or into: (a) the United States, its territories or possessions or to any US Person ("United States"); or (b) Canada, Australia, New Zealand, the Republic of Ireland, the Republic of South Africa or Japan, (together with the United States, being a "Restricted Territory"); or (c) distributed to any individual outside a Restricted Territory who is a citizen, national or resident thereof, or to any corporation, partnership or other entity created or organised under the laws of those. Any such transmission or distribution could result in a violation of relevant securities laws of such jurisdictions.

This Presentation may include certain forward-looking statements, beliefs or opinions relating to the Company and its subsidiaries or proposed subsidiaries (the "Group"), including statements with respect to the Group's business, financial condition and results of operations. These statements also relate to the future prospects, developments and business strategies of the Company and its Group. These statements, which contain words such as "anticipate", "believe", "intend", "estimate", "expect", "forecast", "could", "may", "plan", "predict", "project", "will" or the negative of those variations and words of similar meaning are contained in all sections of the Presentation and reflect the Directors' beliefs and expectations and involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. No representation is made that any of these statements or forecasts will come to pass or that any forecast results will be achieved. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these statements and forecasts. Past performance cannot be relied on as a guide to future performance of the Company or any member of the Group. Forward-looking statements speak only as at the date of this Presentation and the Company expressly disclaims any obligations or undertaking to release any update of, or revisions to, any forward-looking statements in this Presentation. No statement in this Presentation is intended to be a profit forecast. As a result, recipients of this Presentation are cautioned not to place any undue reliance on such forward-looking statements. This Presentation speaks as of the date hereof.

The contents of this Presentation have not been verified, and no reliance may be placed for any purposes whatsoever on the information contained in this Presentation or on its completeness, accuracy or fairness. Any reliance on this Presentation for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested.

The Company, their advisers (including its nominated adviser, Singer Capital Markets Advisory LLP and, its joint brokers, Singer Capital Markets Securities Limited and Oberon Investments Limited (t/a as Oberon Capital)) and each of their respective members, directors, officers and employees are under no obligation to update or keep current the information contained in this Presentation, to correct any inaccuracies which may become apparent, or to publicly announce the result of any revision to the statements made in this Presentation except where they would be required to do so under applicable law, and any opinions expressed in the Presentation are subject to change without notice. None of the Company or any of members of its Group or affiliates or directors, officers or any other person (including any of the advisers to the Company) accepts any responsibility whatsoever, nor makes any representation or warranty, express or implied, as to the fairness, accuracy or completeness of the information or opinions contained in this Presentation and no liability whatsoever for any loss howsoever arising from any use of this Presentation or its contents otherwise arising in connection therewith is accepted by any such person in relation to such information. The Company accordingly disclaims all and any responsibility or liability (whether arising in tort, contract or otherwise) which it may otherwise have in respect of this Presentation or its contents.

If the recipient of this Presentation is in any doubt about the contents of this Presentation and any accompanying materials or any action to be taken, the recipient should consult a person authorised for the purposes of FSMA or from another appropriately authorised advisor if they are taking advice in a territory outside the United Kingdom. By attending or viewing the Presentation you agree to be bound by the foregoing limitations and warrant and undertake to the Company that: (i) you are a relevant person and you will observe the foregoing provisions, limitations and conditions; and (ii) you have read, agree to and will comply with the terms of this disclaimer.



An exciting opportunity for accelerated commercial growth

- Revenue generating suite of next-gen tests for the \$900m kidney transplant market.
- De-risked and moving from product development to commercialization.
 - £37.35m raised to date to fund development, clinical validation and commercial launch.
 - Two products fully validated and commercially available in US.
 - Lead product **Tutivia™** fully reimbursed (\$2,650) by Medicare (68% of US transplant tests).
- Large and growing market opportunity to displace existing tests and address a significant unmet need.
- Licensing agreement with Thermo Fisher for PTRA (Clarava).
- Funding to support scale up of Tutivia™ revenues (test sales, potential licensing royalties).

Our differentiated products

- Suite of blood-based tests for kidney transplant patients **assessing the risk of rejection along the patient journey** from pre-transplant to long-term outcomes. Using RNA sequencing technology to utilise the messaging system of the body to deliver early and precise personalized information.
- **PTRA (Clarava™)** is a pre-transplant test to help define individual patient risk for acute rejection post transplant. This can help clinicians to determine the level of immunosuppression in a more personalised manner. **Licensing agreement with Thermo Fisher.**
- **Tutivia™** is a test for acute rejection post-transplant. A single patient may require multiple tests. **Commercially available & growing revenue generation.**
- **Protega™** is a test for longer term outcomes. The results may help clinicians determine the appropriate care pathways to delay or reduce progressive fibrosis. **Final visits (2-year appointments) for trial subjects completed.**



EARLY



RELIABLE



DYNAMIC



PERSONALIZED

A unique commercial offering


- Technology based upon RNA which is the messaging system of the body and the tests offer benefits comparable to an early warning system. The current dominant technology offered in the market measures injury and is often referred to as a late biomarker.
- **Advanced technology to displace current testing market AND address a large unmet need.**
 - This advance in the underlying technology enables Verici to offer benefits not currently available and to address areas of transplant care that are not served with the current technology.
- **Tutivia™ is commercially available through direct sales channel and Medicare covered.**

Medicare coverage – gateway to growth

- Significant milestone achieved in April 2025 with a positive coverage determination.
- Medicare is the largest payor and accounts for 68% of all transplants in US.
- **\$2,650 reimbursement price** and payment terms 14-21 days (Medicare Advantage 21-30 days).
- Important in-centre adoption:
 - Credibility and status.
 - Ease of process.
- Comprehensive coverage (others have exclusions).
- Sets precedent for commercial payors - process underway.



Significant volume acceleration in H1




- Q3 volume consistent with previous two quarters at 286 orders, with a doubling from newer centres.
- Expected growth in Q4.

- 30 transplant centres onboarded:
 - Increase of 9 centres and 19% increase in ordering clinicians in Q3.
 - These centres represent 16% of annual transplants and so well poised for growth.



Targeted growth – easy wins where we have no competition



What is the addressable market in US?

- 28,000 kidney transplants take place each year in the US – and this number is growing.
- Current clinical protocols use an average of 12 testing points for each patient.
- This gives an estimated addressable market of \$900m.

Why are more than 1/3 of patients not tested?

- Traditional biomarkers cannot be used with well over 1/3 of the patient population:
 - Delayed Graft Function (26%).* 40-60% currently
 - BK nephropathy (12%).*
 - Prior kidney transplant (12%).*
 - Belatacept Conversion (10%).*
 - Multiple organ transplants (8%).*
- Tutivia's technology addresses these populations as well as offering advantages for the existing tested patients.

Funds in place to drive strong Tutivia™ sales growth

End of July funding has enabled us to:

- Hire 2 Senior Sales with another to join in October.
- Hire a clinical resource for the sales team.
- Fund KOL events at WTC.
- Expand KOL presence on our Science Advisory Board.
- Jointly fund 2 events with Thermo.
- Start the private payor process with consulting support with some early wins.
- Continue to target meeting market expectations for the full year (\$3.2m test revenues), although growth financing was secured later in the year than hoped.
- Medicare price of \$2,650 with private payors likely to be lower – assumed average reimbursement price \$1,960 with assumptions about commercial payors maintained as too early to update.
- New hires are already contributing ahead of internal expectations - prior expectation was that new hires will need 6 months of support with impact only seen in FY26.

PTRA (Clarava™) license with Thermo Fisher

Milestone progress

- Pre-Transplant Risk Assessment Test (PTRA) was licensed to Thermo Fisher in Q4 2023.
- Successfully transferred and launched in 2024.
- Health Economics delivered 2025.
- Sales volume based milestone & ongoing royalties outstanding.



Commercial progress

- Thermo Fisher remain positive and are investing further in PTRA team.
- Thermo Fisher investment in studies to support expanded approach to market with a likely positive impact on testing frequency.
- Hosted a Joint Symposium at industry conference.
- Focus on key publications and KOL engagement.
- Strong ongoing relationship with interest in other opportunities.



Challenges with standardized immunosuppression protocols

Personalized consultative service and support

Provides information about patient risk and may inform post transplant immunosuppression

This enhanced risk assessment is the first test of its kind to provide information about patient risk of early acute rejection with high (NPV= 96.7); based on a patient's unique gene profile prior to transplant.¹ Data from this test may help clinicians make more informed decisions about post-transplant management and better balance the risk of rejection against the adverse effects of over-immunosuppression.




Pipeline update

- Product development pipeline has unique competitive positioning opportunities.
 - Urine platform.
 - Protega™ - Fibrosis based testing market applies beyond transplant.
- Product development timing pushed out to end of the year in response to market and company conditions.

De-risked & ready for commercial scale up

Achieved to date

- 2 Products fully validated & commercially available;
 - 1 product licensed to major strategic partner.
 - 1 product launched through direct sales channel.
- All commercialisation requirements in place:
 - Lab and Logistics.
 - Regulatory.
 - Reimbursement; code price coverage.
- Early adopter revenue growth (30 ordering centres - hospitals).
- 2 additional products in pipeline with all clinical validation data points completed.



Growth Opportunity

- Tutivia™ revenue scale up.
- \$900m US addressable market.
- Tailwinds in the industry.
- Existing centres account for c10% of annual transplants.

TUTIVIA
Delivers

Financial Report



Financial highlights

- Revenue of \$1.9m in the period:
 - \$1.16 from *Tutivia* testing revenue. *First revenues recognized.*
 - \$0.75m from *Thermo Fisher* licensing.
- EBITDA loss of \$2.8m (H1 2024 \$1.1m; FY 2024 \$5.4m).
- Net cash outflow from operating activities \$3.5m (H1 2024 \$3.2m; FY 2024 \$6.0m).
- Post-period end fund raise of Gross £6.35m (\$8.4m net), Net £5.8m (\$7.7m net).
- Cash at end of June \$0.5m – cash at end of September c.\$5.3m.
- Expected cash runway into at least H2 2026.



How revenues are recognised

- There are 6 different inputs into the calculation of revenue:
 - *Number of tests ordered.*
 - *Number of tests resulted.*
 - *Medicare reimbursement price.*
 - *Commercial payors average reimbursement.*
 - *Commercial payors denial rate.*
 - *Split between Medicare and Commercial payors.*
- Of these we only have certainty over the Medicare reimbursement price of \$2,650, from which a 2% charge is taken.
- We will have more information by year end on these other variables to better inform the calculation of our revenues.



Cash Flow Statement

Six months to 30 June	2025
	\$'000
Net cash outflow from operating activities	(3,520)
Investing activities	(43)
Financing activities	(98)
Net cash (decrease) / increase	(3,661)
Cash at 30 June	467

- From revenues we received the \$0.75m in the period but much of the Tutivia testing income held in receivables, with the balance at 30 June of \$792k so not flowing into cash in the period.
- Investing activities: spend on the patent portfolio.
- Financing: rent and capital lease payments.



Income Statement

Six months to 30 June	2025
	\$'000
Revenues	1,913
Cost of sales	(352)
Administrative expenses	(4,229)
Share based payments charge	(132)
EBITDA	(2,800)

- Revenues: Tutivia \$1,163k and License \$750k.
- Cost of sales: all relate to Tutivia. Gross margin 70%.
- Administrative:
 - Largest expense payroll at \$2,071k.
 - R&D spend continues to fall at \$652k.
 - Increasing spend on sales support at \$538k.



Balance Sheet

At 30 June	2025 \$'000
Trade and other receivables	1,282
Cash	467
Non-current assets	2,796
Trade and other payables	(1,781)
Lease liabilities	(282)
Net assets	2,482

- Trade receivables of \$792k from Tutiva revenue.
- Non-current: \$2,144 on intangible asset.
- Payables: \$350k of site accruals invoiced in June, leaving balance of \$400k.
- Lease liabilities: capital lease and rental liability on laboratory in TN.

Post BS event fundraise £5.8m/\$7.7m at end of July



SUMMARY & OUTLOOK

- Exciting opportunity to deliver accelerated growth in the c. \$900m kidney transplant market.
- De-risked business with two products now fully validated and commercially available.
 - Lead product **Tutivia™** fully reimbursed (\$2,650) by Medicare (nationally 68% of transplant tests).
 - Increasing test adoption: 591 **Tutivia™** tests ordered in H1 2025 (334 for the whole of FY 2024).
 - Total of 30 transplant centres onboarded – representing 16% of annual US transplant volume.
 - Continued progress with Thermo Fisher PTRA license.
- Well poised for growth: significant testing volume acceleration expected in H2 2025 and beyond.
- Commercial team expanded with the addition of three sales people and a Director of Clinical Partnerships to join in Mid-October.





Questions

